ISTH 2020 Congress Archives - ISTH Congress Abstracts

Abstract Number: PB2286

Radiological Parameters on Computed Tomography Pulmonary Angiography Correlate Poorly with Early Mortality from Acute Pulmonary Embolism

I. Wu¹, P.I. Ngam², C.C. Ong², W. Kristanto³, P. Kojodjojo³, L. Teo², Y.L. Chee¹, W.Y. Jen¹
Abstract Number: PB1160

Raising Factor VIII’s Half-life to the Next Level

S. Kistner¹, J. Daufenbach¹, P. Herbener¹, J. Schüttrumpf²
Abstract Number: PB1360

Randomized Study for the Treatment of Primary Immune Thrombocytopenic Purpura (pITP) in Newly Diagnosed Untreated Adult Patients. Comparison of Standard Dose Prednisone versus High-dose Dexamethasone. Preliminary Results. GIMEMA Protocol ITP0207

M.G. Mazzucconi¹, F. Paoloni², A. Sau³, N. Vianelli⁴, I. Vincelli⁵, M. Ruggeri⁶, E. Rivolti⁷, L. Gugliotta⁷, G. Gaidano⁸, M. Napolitano⁹, N. Cascavilla¹⁰, C. Carbone¹¹, V. Pavone¹², V. De Stefano¹³, G. Avvisati¹⁴, M. Iodice², E. Baldacci¹, P. Fazi², F. Rodeghiero⁶, C. Santoro¹
Abstract Number: PB1618

Rap1a/b Isoforms Differentially Regulate Megakaryocyte Biology

D. Ghalloussi¹, G. Harousseau¹, A. Eckly², J.P. Kenny¹, C. Kirkpatrick¹, E.C. O'Shaughnessy³, K. Hahn³, C. Gachet², L. Stefanini⁴, K. Eto⁵, W. Bergmeier¹
Abstract Number: PB1064

Rapid Desensitization and Subsequent Immune Tolerance Induction in a Patient with Hypersensitivity and Inhibitor to Factor VIII

W. Mitchell
Abstract Number: PB0686

Rapid Latex Enhanced Immunoassay (LIA) for Heparin Induced Thrombocytopenia and False Positivity

D. Welder¹, F. Compton¹, N. De Simone¹, S. Nagalla², S. Rambally², C. Webb¹, R. Sarode^1,2
Abstract Number: PB0307

Rapid Thaw Plasma Units Thaw Significantly Faster than Standard Plasma Units while Retaining Similar Coagulation Profile over 5 Days of Cold Storage

K.M. Madden¹, J.S. Raval¹, L. Rosenbaum^1,2, C. Richards³, C. Jones³, P. Lowery³, M.A. Rollins-Raval¹
Abstract Number: PB0207

Rare Bleeding Disorders in North India – Study from a Tertiary Care Centre

S. Langer¹, D. Gupta¹, P. Sachdeva², M. Kalra², A. Sachdeva², A. Sharma³, J. Kotwal¹
Abstract Number: PB1167

Rare Bleeding Disorders in Southern Iran: Revisited and Updated Data

M. Bordbar¹, M. Karimi¹, A. Shahsavani^1,2, S. Haghpanah¹
Abstract Number: PB0176

Rare Coagulation Disorders in Children – Is it Like to Buy a Pig in a Poke or Nothing Special? Experience of Saint Petersburg, Russia

N. Sokolova, N. Vaynyunskaya
Abstract Number: PB2059

Rates, Management and Outcome of Bleeding Complications during Edoxaban Therapy in Daily Care – Results from the Dresden NOAC Registry

J. Beyer-Westendorf, S. Marten, L. Tittl, C. Naue
Abstract Number: PB2050

Ratio of Inhibited Thrombin Generation Based on Dilute Prothrombin Time May Predict the Major Bleeding or Thrombotic Tendency in NVAF Patients Treated with Anti-Xa DOAC

K. Ohmura¹, M. Ieko¹, S. Naito², M. Yoshida², N. Takahashi¹, S. Ono³, I. Sakuma⁴
Abstract Number: PB0120

Rationale and Design for the Study Apixaban versus ClopidoGRel on a Background of Aspirin in Patients Undergoing InfraPoPliteal Angioplasty for Critical Limb Ischemia – AGRIPPA Trial

R. Biagioni¹, R. Lopes², L. Agati³, E. Ramacciotti^4,5
Abstract Number: PB0910

Rationale and Study Design for a Prospective, Low-Interventional Study to Investigate whether Systematic Joint Examination Impacts Haemophilia Treatment Management Decisions in Patients with Haemophilia A in France: The A-MOVE Study

Y. Repessé¹, J. Courias², C. Gandossi²
Abstract Number: PB2371

Real Life Experience of an Antithrombotic Stewardship Program for Thrombosis Prophylaxis during Hospitalisation in a Large Teaching Hospital

M. Taskopru¹, M. Slijkhuis², S. van Wissen³, N. Khorsand⁴
Abstract Number: PB0785

Real Life Experienceon 61 Acquired Haemophilia A (AHA) Patients from a Single Center

M. Porrazzo, A. Ferretti, E. Baldacci, S. Aprile, F. Barone, R. Abbruzzese, A. Chistolini, M.G. Mazzucconi, C. Santoro
Abstract Number: PB0877

Real Life Use of Emicizumab in Pediatric Patients without Inhibitors

S.I. Heine, N. Graf
Abstract Number: PB0935

Real World Efficacy of Emicizumab in Haemophilia A with Inhibitors: A Report from the UK National Haemophilia Database

C. Wall¹, H. Xiang², B. Palmer², P. Collins³, D. Hart⁴, G. Hall⁵, E. Chalmers⁶, G. Benson⁷, G. Evans⁸, R. Liesner⁹, M. Makris¹⁰, C. Harrison¹⁰, S. Mangles¹¹, R. Maclean¹⁰, S. Shapiro¹², D. Stephensen⁸, P. Sartain¹³, C. Hay²
Abstract Number: PB1591

Real World Experience of Major Surgery and Delivery in Von Willebrand Disease

B. Craven¹, M.R. Peralta², A. Riddell², T.T. Yee²
Abstract Number: PB0796

Real World Experience on Use of Susoctocog-alfa (rpFVIII) in the Treatment of a Population of Italian Elderly Patients with Acquired Haemophilia A

E. Zanon¹, S. Pasca¹, A. Borchiellini², C. Lodigiani³, A.C. Molinari⁴, P. Moscatelli⁵, C. Ambaglio⁶, P.S. Preti⁶, P. Simioni⁷
Abstract Number: PB1072

Real World Experience with Rurioctocog Alfa Pegol in Vall d´Hebron University Hospital

G. Robayo Buitrago¹, J.C. Juarez², O. Benitez¹, M.F. Martinez¹, M. Suito³, E. Alvarez¹, M. Gironella⁴, F. Bosch⁴
Abstract Number: PB0349

Real-life Inter-individual Variability of Pharmacokinetics – Reason for Individualization of Replacement Therapy in Haemophilia

A. Traila¹, C.E. Ursu², D. Savescu², F. Horhat³, M. Chincesan⁴, J.M.J. Patrascu³, C. Jinca³, M. Serban², W. Schramm⁵, S. Arghirescu³
Abstract Number: PB1550

Real-life Management of Digestive Endoscopies: Is There a Bleeding Risk for Patients with von Willebrand Disease?

V. Horvais¹, B. Guillet², P. Beurrier³, V. Cussac⁴, B. Pan-Petesch⁵, N. Baty³, S. Cochennec², G. Drugmanne⁵, S. Bayart², J. Rose⁴, F. Nedelec-Gac², N. Drillaud¹, M. Sigaud¹, M. Fouassier¹, C. Ternisien¹, M. Trossaert¹, the BERHLINGO Group
Abstract Number: PB0148

Real-time in vivo Visualization of Infused FVIIa in Hemophilia A Mice Following Injury

J.C. Small¹, T.J. Stalker², L. Dankner¹, S.M. Zintner¹, P. Margaritis²
Abstract Number: PB0655

Real-time Intra-site and Multi-site Correlations and Evaluation of Time Stability with the Same Frozen Plasmas Kits which Cover the Full Measuring Range for Routine Tests and Anticoagulant Monitoring Tests

C. Flaujac¹, I. Amouroux², P. Manzi¹, S. Doan¹, L. Germain², J. Dieu², S. Pinheiro Vaz¹, P. Plu¹, E. Saksik¹, S. Zia-Chahabi¹
Abstract Number: PB0340

Real-world Analysis of Hemophilia Patients in China: A Single Center’s Experience

X. Song, F. Xue, L. Zhang, Y. Yang, R. Yang
Abstract Number: PB0873

Real-World Cost of Emicizumab

A.L. Dunn^1,2, N. Toocheck³, M. Hallam¹, C. Soller⁴, M. Storey⁵
Abstract Number: PB0948

Real-World Data of First-Time and Rescue Immune Tolerance Induction with Recombinant Factor VIII Fc Fusion Protein in Patients with Hemophilia A with Inhibitors in Japan: “Fc Adolescent and Children Treatment” Study (FACTs) Part 2 Interim Analysis

M. Taki¹, K. Nogami², C. Nagae¹, A. Nagao³, K. Moritani⁴, K. Koh⁵, M. Shiraishi⁶, M. Takatoku⁶, M. Shima²
Abstract Number: PB0879

Real-World Effectiveness Evaluation of the Recombinant Factor VIII Fc Fusion Protein in Adolescents and Children with Hemophilia A in Japan: “Fc Adolescent and Children Treatment” Study (FACTs) Part 1 Interim Analysis

M. Kobayashi¹, T. Matsushita², K. Nogami³, I. Usami⁴, M. Shiraishi⁵, M. Takatoku⁵
Abstract Number: PB1051

Real-world Evidence on the Use of rIX-FP in Patients with Hemophilia B: Interim Results from Three Multinational Prospective, Non-interventional, Post-market Surveillance Studies

A. Tagliaferri¹, J. Oldenburg², K. Peerlinck³, G. Castaman⁴
Abstract Number: PB0980

Real-World Experience of rVIII-SingleChain Treatment in a French Single Center

A.A. Hassoun
Abstract Number: PB0928

Real-World Experience with Emicizumab in Persons with Hemophilia A (HA) with or without Inhibitors

M. Lewandowska, N. Randall, J. Maahs, N. Bakeer, J. Sagar, A. Greist, A. Shapiro
Abstract Number: PB0919

Real-World Outcomes before and after Switching from Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in the United States

S.X. Sun¹, S. Milligan²
Abstract Number: PB0779

Real-World Use of Recombinant B-Domain-Deleted, Porcine-Sequence Factor VIII in Patients with Acquired Hemophilia A: An Interim Analysis of the Post-Authorization Safety Study in the European Union (EU)

W. Miesbach¹, C. Ambaglio², P. Knoebl³, C. Lodigiani⁴, R. Santoro⁵, J. Chen⁶, N. Tripkovic⁷, R. Klamroth⁸
Abstract Number: PB2394

Reasons and Associated Outcomes in Delayed Anticoagulation in Venous Thromboembolism

N.E. Brunton¹, W.E. Wysokinski², D.O. Hodges³, D.T. Vlazny², D.E. Houghton², A. Casanegra⁴
Abstract Number: PB2511

Reassessment of Venous Thromboembolism Risk and Prophylaxis in Post-Delivery Period of Healthy Women

A. Braester^1,2, J. Borenstein^2,3, A. Zverev³, E. Kukuyev⁴, E. Shaoul⁴, G. Stemer⁵, M. Barhoum^4,6
Abstract Number: PB2208

Recanalization of Venous Thrombosis by Robotic Assisted High Frequency Pulsed Cavitational Ultrasound Therapy: 2 Weeks Follow-up in a Swine Model

L. Khider^1,2, G. Goudot¹, C. Del Giudice³, T. Mirault¹, A. Galloula¹, P. Bruneval⁴, M. Tanter², M. Pernot², E. Messas¹
Abstract Number: PB1545

Recombinant Human von Willebrand Factor (rVWF) Differs in Structure and Function from Plasma Derived Concentrates

H. Gritsch¹, G. Schrenk¹, N. Weinhappl¹, B. Mellgård², B. Ewenstein², F. Truong Berthoz³, P.L. Turecek¹
Abstract Number: PB1558

Recombinant von Willebrand Factor (rVWF) in Patients with von Willebrand Disease (VWD) Undergoing Elective or Emergency Surgery in Real World Setting – The Dijon University Hospital Experience from March 2019 to January 2020

F. Genre Volot¹, A. Callegarin², E. de Maistre²
Abstract Number: PB1224

Recommendation on the Treatment of Venous Thromboembolism in Cancer Patients at a Brazilian Public Oncological Institution: Educational Plan

C. Rothschild¹, N. De L. Nedach², A. P. Rabelo³, P. R. Souza³, G. B.G. Faria³, M.R.S. Maria R. Silva⁴, A. A.G.S. Brandão¹, M.D.P. E. Diz⁵, J. Pereira⁶, V. Rocha⁶
Abstract Number: PB2328

Recovery from Acute Kidney Injury in Patients with Pulmonary Embolism: A Monocenter Study

M. Murgier¹, L. Fouillet¹, E. Ollier¹, A. Merah¹, N. Moulin¹, S. Accassat¹, C. Duvillard¹, E. De Magalhaes¹, P. Mismetti¹, M. Monreal², L. Bertoletti¹
Abstract Number: PB1937

Recurrence of Thrombotic Events in Antiphospholipid Syndrome Patients Receiving Prolonged Vitamin K Antagonists Therapy

M. Sousa, G. Oliveira, C. Koch
Abstract Number: PB0397

Red Blood Cells Support Factor X Activation via Intrinsic Tenase

I.A. Chabin^1,2, N.A. Podoplelova^1,3, F.I. Ataullakhanov^1,3,4, M.A. Panteleev^1,3,4
Abstract Number: PB1963

Redox Regulation of Neutrophil Mac-1 Function by Protein Disulphide Isomerase

A. Dupuy^1,2, S. Oehlers^1,3, L. Hagimola¹, C. Gomez¹, S. Zheng², P. Hogg^1,3, J. Chiu^1,3, F. Passam^1,2,4
Abstract Number: PB2041

Reduced Bleeding After an Intervention to Limit Excess Aspirin Use Among Patients on Chronic Warfarin

J.K. Schaefer¹, J. Errickson², X. Gu³, T. Alexandris-Souphis³, M.A. Ali⁴, B. Haymart³, S. Kaatz⁵, E. Kline-Rogers³, J.H. Kozlowski⁶, G.D. Krol⁵, V. Shah⁵, S.L. Sood⁷, J.B. Froehlich³, G.D. Barnes³
Abstract Number: PB1532

Reduced Cleavage of Circulating Ultra-large von Willebrand Factor by ADAMTS13 Exacerbates Microvascular Disease Following Traumatic Injury

W. Plautz¹, S. Haldeman², M. Dyer², M. Neal²
Abstract Number: PB1642

Reduced GPVI Signalling in Genetic and Disease Models of Thrombocytopenia

S.R. Hyslop^1,2, M. Lebois^1,2, J. Corbin², P. Gangatirkar², K.D. Sutherland^1,2, R.K. Andrews³, E.E. Gardiner⁴, W.S. Alexander^1,5, E.C. Josefsson^1,2
Abstract Number: PB0834

Reduced Splenic T Cells Count in an Untreated Mouse Model of Severe Hemophilia A

C. Borsotti, V. Kalandadze, I. Mohammed, P. Di Simone, A. Follenzi
Abstract Number: OC 01.4

Reduction of Intracellular Sodium Protects from Inflammation and Atherosclerotic Plaque Progression

M. Lenz¹, C. Kaun¹, A. Rehberger², M. Sebestjen², C. Binder³, K. Huber⁴, C. Hengstenberg¹, J. Wojta¹, W. Speidl¹, P. Hohensinner¹
Abstract Number: PB2548

Reduction of Thromboembolic Disorders in Pregnancy and Postpartum Period: Role of National Pregnancy Heart Team

I. Davydova^1,2, S. Siromakha³, A. Rusnak⁴, A. Ogorodnyk¹, V. Lazoryshynets⁵
Abstract Number: PB/CO18

Reduction of Venous Thromboembolic Events in Hospitalized Patients with Coronavirus Disease 2019 after Intensification of Thromboprophylaxis

P. Filippidis¹, E. Kampouri¹, B. Viala¹, M. Méan¹, O. Pantet¹, F. Desgranges¹, J. Tschopp¹, J. Regina¹, E. Karachalias², C. Bianchi¹, M. Zermatten¹, K. Jaton¹, S.D. Qanadli¹, P.-A. Bart¹, J.-L. Pagani¹, B. Guery¹, M. Papadimitriou-Olivgeris¹, L. Alberio¹
Abstract Number: PB1743

Reelin Modulates Glycoprotein VI and Integrin Outside-in Signaling of Platelets

I. Krueger¹, H. Bock², M. Elvers¹
Abstract Number: PB2568

Reference Ranges for Hemostasis Parameters during ¨Pregnancy and Puerperium

V. Potylitsina^1,2, Y. Raspopin^1,2, I. Olkhovsky^3,4, P. Toulon⁵
Abstract Number: PB1032

Reference Ranges of HJHS Scores in Healthy Adult Males without Hemophilia

J. St-Louis¹, A. Abad², S. Akins³, S. Austin⁴, P. Chowdary⁵, S. Classey⁴, S. Funk⁶, G. Hernandez⁷, P. Hilliard², M. Manco-Johnson⁶, S. Mangles⁸, P. McLaughlin⁵, D. Nugent⁷, A. Shapiro³, A. Srivastava⁹, M. Tilak⁹, A. Wells⁸, N. Zourikian¹, V. Blanchette², B.M. Feldman²
Abstract Number: PB0601

Reference Values of 117 Healthy Donors on the ST Genesia with the STG-BleedScreen, STG-DrugScreen and STG-ThromboScreen Reagents

M. Ninivaggi¹, R. de Laat-Kremers¹, A. Carlo², B. de Laat¹
Abstract Number: PB1442

Refractory Thrombocytopenia with TUBB1 Variants: Clinical Features and Responses to Eltrombopag Treatment

M. Jiang¹, G. Sheng², J. Yin², X. Wang², Z. Yu², C. Ruan²
Abstract Number: PB1865

Relapsing or Refractory Thrombotic Microangiopathies: The Key Role of ADAMTS13 Activity and Complement Testing

E. Gavriilaki¹, E.-E. Koravou¹, T. Chatzikonstantinou¹, C. Kalpadaki², N. Printza³, M. Ximeri², A. Christoforidou⁴, G. Karavalakis⁵, I. Tassi⁶, M. Tzellou⁷, A. Spyridonidis⁸, E. Kapsali⁶, K. Kollios⁷, E. Mandala⁹, E. Vlachaki¹⁰, P. Tsirigotis¹¹, E. Papadaki², C. Lalayanni¹, I. Sakellari¹, A. Anagnostopoulos¹, Thrombotic Microangiopathy Study Group
Abstract Number: PB2239

Relation between the von Willebrand Factor and ADAMTS13 with Venous Thrombosis Risk. Results from the Retrove Project

D. Llobet¹, C. Vallvé¹, A. Oliver², M. Carrasco¹, N. Vilalta¹, J. Mateo¹, J.C. Souto¹
Abstract Number: PB0042

Relationship between Distal Venous Thrombosis and Asymptomatic Atherosclerotic Disease

A. Adamo, L. Spiezia, F. Dalla Valle, G. Avruscio, P. Simioni
Abstract Number: PB1787

Relationship between HAART treatment and Markers of Coagulation among People Living with HIV/AIDS (PLWHA) in Gombe, Nigeria

S. Adamu^1,2, G. Aglavdawa³, S.A. Ufelle⁴, S. Yuguda^3,5, A.I. Girei^3,5, Y.M. Sherrif³
Abstract Number: PB1333

Relationship between Platelet Function and Glycome Composition in Immune Thrombocytopenia

E. Monzon Manzano¹, P. Acuña¹, M.T. Álvarez Román¹, M. Martín Salces¹, M.I. Rivas Pollmar¹, I. Fernández Bello¹, V. Jiménez Yuste^1,2, N. Butta¹
Abstract Number: PB2042

Relationship between TTR and Daily Vitamin K Intake in Patients Taking Warfarin: The Difference among VKORC1 Genotype

T. Nagao¹, K. Yasunishi², H. Kumagai², E. Kodani³, K. Kimura⁴
Abstract Number: PB2066

Relationship of Health Literacy and Adherence to Treatment with Oral Anticoagulants in Patients with Atrial Fibrillation in Brazil

F. Bartolazzi¹, A.L.P. Ribeiro¹, W.J.F.N. Sousa¹, J.L.P. Silva², M.S. Vianna³, M.F.d.S. Praxedes⁴, M.A.P. Martins^1,3
Abstract Number: PB2338

Relevance of Immobility as Deep Vein Thrombosis Risk Factor for Medically Ill Patients

M. Sartori, E. Favaretto, B. Cosmi
Abstract Number: PB0265

Relevance of Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 p.Thr309Lys Variant

M.E. de la Morena-Barrio¹, R. Lopez-Galvez¹, A. Miñano¹, V. Vicente¹, J. Emsley², J. Corral¹, A. Lopez-Lera³
Abstract Number: PB2234

Relevance of Thrombophilia Screening in Adult Renal Transplant Recipients

D. Bahri¹, H. Baccouche¹, L. Ben Fatma², S. Hadded², A. Chakroun¹, S. Mahjoub¹, M.K. Zouaghi², N. Ben Romdhane¹
Abstract Number: PB0145

Reported Values and Methodologies for Detecting Plasma D-dimer in Rat Models: A Systematic Review and Meta-analysis

J. Chung^1,2, S. Afraz^2,3, D. Matino^2,4, A. Chan^2,3,4
Abstract Number: PB1156

Rescue of the Endogenous FVIII Expression in Hemophilia A Mice Using CRISPR/Cas9 Gene Editing

C.-Y. Chen¹, X. Cai¹, C. Miao^1,2
Abstract Number: PB0882

Resolution of Target Joints (TJs) in Children with Severe Haemophilia A (HA) Treated with Turoctocog Alfa Pegol (N8-GP) Prophylaxis: Results from the Pathfinder 5 Trial

S.S. Trakymienė¹, C. Shen², S. Benchikh El Fegoun³, A. Landorph²
Abstract Number: PB1363

Response Rate and Response Duration after Discontinuation of Treatment with Thrombopoietin Receptor Agonists (TPO-RAS) in Patients Affected by Primary Immune Thrombocytopenia (pITP): Retrospective Study. Preliminary Results. GIMEMA Protocol ITP0714

M.G. Mazzucconi¹, F. Paoloni², M. Carpenedo³, V. De Stefano⁴, S. Cantoni⁵, N. Vianelli⁶, M. Iodice², E. Baldacci¹, F. Zaja⁷, A. Bosi⁸, P. Schinco⁹, P. Fazi², F. Rodeghiero¹⁰, C. Santoro¹
Abstract Number: PB1349

Response to Avatrombopag (AVA) in Chronic Immune Thrombocytopenia: Alternative Efficacy Measures

H. Maitland¹, K. Aggarwal², M. Vredenburg², W. Tian², N. Gabrail³
Abstract Number: PB1571

Response to Desmopressin Acetate in Von Willebrand Disease Type 2

G.A. Maia^1,2, S.D.S. Freitas¹, P.S.R. Cardoso^1,3, L.C. Oliveira⁴, D.G. Chaves³, S.M. Rezende¹
Abstract Number: PB1549

Response to Treatment for Gastro-Intestinal Bleeding in von Willebrand Disease

E. Biguzzi¹, S.M. Siboni¹, R. Gualtierotti², S. Braham¹, M.T. Pagliari³, F. Peyvandi^3,4
Abstract Number: PB1169

Results from a Phase 4, Real-World Study Confirm the Safety and Effectiveness of rFXIII-A2 for the Treatment of Congenital FXIII A-Subunit Deficiency

L. Hvitfeldt Poulsen¹, B.A. Kerlin², G. Castaman³, A.C. Molinari⁴, M. Menegatti⁵, S. Dey⁶, M.-L. Garly⁷, M. Carcao⁸
Abstract Number: PB2213

Results of a Dedicated Diagnostic Work-up of Patients with Post-PE Syndrome

G.J.A.M. Boon¹, S.M.J. Janssen², H.J. Bogaard³, L.J.M. Kroft⁴, L.J. Meijboom⁵, M.K. Ninaber⁶, E.J. Nossent⁷, P. Symersky⁸, H.W. Vliegen⁹, A. Vonk Noordegraaf⁷, M.V. Huisman¹, J.J. Abbink², F.A. Klok¹
Abstract Number: PB0653

Results of Anti-Xa Activities for Monitoring Therapeutic and Prophylactic Doses of Low Molecular Weight Heparin in Children

J. Obuljen¹, G. Jakovljević², S. Margetić³, I. Linarić¹, J. Leniček Krleža¹
Abstract Number: PB2332

Retinal Vein Thrombosis and the Association with Inherited Thrombophilia, Cardiovascular Risk Factors and the Risk of Occult Cancer. a Prospective Study

D. Tormene¹, G. Turatti¹, C. Simion¹, M. Marobin², S. Gavasso¹, E. Campello¹, P. Simioni¹
Abstract Number: PB1237

Retrospective Analysis of Characteristics and Outcomes of 340 Pediatric ITP Patients in One Center

R. Li¹, R. Yang²
Abstract Number: PB1555

Retrospective Chart Review of Gastrointestinal Bleeding in Patients with von Willebrand Disease: Study Design and Initial Demographic Results

J.C. Roberts¹, M. Escobar², S. Acharya³, N.X. Hwang⁴, M. Wang⁵, S.A. Hale⁶, A. Oladapo⁶, S. Asghar⁷, P.A. Kouides⁸
Abstract Number: PB1870

Retrospective Study of 30 TTP Patients from 2017 to 2019 in a Single Center of Suzhou, China

J. Yin, Z. Yu, Z. Wang, D. Kong, J. Su, M. Jiang, C. Ruan
Abstract Number: PB2438

Retrospective Study of Patients with Upper Extremity Clots Presenting to Emergency Departments in Tertiary Care Hospitals in a Major Canadian City in the Last Five Years

T. Pannu¹, E. Herget², D. Suryanarayan¹
Abstract Number: PB0317

Reversal of Dabigatran by Idarucizumab in Heart Transplantation Surgery: A Case Report

F. Robles de Vasconcelos, C. Vaz, L. Ricca Gonçalves, C. Monteiro, D. Aranda, M.C. Koch
Abstract Number: PB1112

Reversal of Direct Oral Anticoagulants with Three-Factor Prothrombin Complex Concentrate: Real World Experience from a Tertiary Centre in Hong Kong

S.Y. Kong, S.F. Yip, C.Y. Ha
Abstract Number: PB0306

Reversal of Heparin Anticoagulation by Andexanet Alfa (Andexanet) in Human Plasma and Whole Blood: Differential Effect of Andexanet on Antithrombin-Dependent Anticoagulants and Direct Thrombin Inhibitors (DTIs)

G. Lu, K. Bui, J.T. Curnutte, P.B. Conley
Abstract Number: PB1069

rFIXFc at Lower Doses Can Achieve Very Significant Reduction of Annualized Bleed Rates in Children with Severe Haemophilia B

A. Abraham¹, F. N.A², R.G. Dave³, S.C. Nair³, A.S. Singh², U.P. Kulkarni², A.J. Devasia², A. Korula², K. M L², B. George², V. Mathews², A. Srivastava²
Abstract Number: PB1061

rFVIIIFc at Lower Doses Can Achieve Clinically Meaningful Reduction of Annualized Bleed Rates in Children with Severe Haemophilia A

A. Abraham¹, F. N.A¹, T. Geevar², S.C. Nair², A.S. Singh¹, U.P. Kulkarni¹, A.J. Devasia¹, A. Korula¹, K. M L¹, B. George¹, V. Mathews¹, A. Srivastava¹
Abstract Number: PB1277

Right Atrial Thrombosis in Children: Patient Characteristics, Outcomes, and Interrater Reliability of Echocardiographic Characterization

B.T. Barnes¹, W. Ravekes¹, G. Freire², E. Amankwah^3,4, J. Chiu⁵, A.R. Sellers^6,7, D. Procaccini^1,8, C.M. Takemoto^9,10, N. Goldenberg^6,9,11
Abstract Number: PB2302

Right Ventricular to Left Ventricular Diameter Ratio Assessment with Non-ECG Gated Computed Tomography Scans and its Correlation with Right Ventricular Dysfunction in Acute Pulmonary Embolism

J. Bilbao¹, J. Bonorino¹, H. Fernandez¹, C. Ferrario², K. Palacio², R. Melchiori¹, P. Colimodio³, P. Alarcon¹, N. Torres¹, M. Iwanowski¹, J. Santucci¹, E. Ortis¹, S. Krause¹, R. Della Cella¹, N. Perez Caceres¹, A. Sanchez¹, S. Marquez¹, P. Rubio¹, S. Baratta¹, A. Hita¹
Abstract Number: PB2350

Risk Factors and Frequency of Recurrent Long-Term Venous Thromboembolism After Superficial Vein Thrombosis of The Lower Limbs

K.M. Nikolakopoulos, S. Kakkos, C.P. Papageorgopoulou, I. Ntouvas, S. Papadoulas, A. Kouri, P. Tsantrizos
Abstract Number: PB2306

Risk Factors and Hemostatic Aspects of Aseptic Cerebral Venous Sinus Thrombosis

K. Stepanchenko¹, V. Marchenko¹, A. Zhidkova², T. Donnik², I. Feday²
Abstract Number: PB2316

Risk Factors and Patterns of Lower Limb Deep Venous Thrombosis in Gombe, North-Eastern Nigeria

S. Yuguda^1,2, A.I. Girei^1,2, K.M. Pindiga², R.A. Dachi³, A.U. Usman^4,5, H.U. Faoruk^6,7, A. Saidu⁸
Abstract Number: PB1878

Risk Factors Associated with Severe Neurological Symptoms in Thrombotic Thrombocytopenic Purpura (TTP)

J.T.S. Castro¹, B.D.M. Mazetto², A.P. Rosa², G. Yamagutti², E.V. Paulo³, J.A. Bizachi³, F. Reis¹, F.A. Orsi³
Abstract Number: PB2539

Risk Factors for Severe Preeclampsia in Obstetric Antiphospholipid Syndrome (OAPS) with Conventional Treatment

G. de Larrañaga¹, O. Latino², S. Udry¹, S. Perés Wingeyer¹, F. Aranda¹, V. Lara¹, D.S. Fernández Romero²
Abstract Number: PB1308

Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents with Lymphomas

D. Evstratov¹, P. Zharkov², N. Myakova¹
Abstract Number: PB1307

Risk Factors for the Development of Hospital-acquired Pediatric Thromboembolism – Dealing with Potentially Causal and Confounding Risk Factors Using Direct Acyclic Graph (DAG) Analysis

L. R. Campos^1,2, M. Petroli^1,3, F. R Sztajnbok^1,4, E.S. Costa¹, L. R Brandao⁵, M. G. P. Land^1,6
Abstract Number: OC 12.4

Risk Factors for Venous and Arterial Thrombosis in the Neonatal Intensive Care Unit (NICU)-A Multicenter Case Control Analysis

R. Bhat¹, S. Kwon², I. Zaniletti³, K. Murthy⁴, R. Liem¹
Abstract Number: PB2426

Risk Factors of Hemorrhagic Complications on the Anticoagulant Therapy

N. Vorobyeva¹, A. Schapkov²
Abstract Number: PB2312

Risk Factors of Thrombotic Complications in Thai Thalassemia Patients

N. Hantrakun, T. Kunlayawutipong, L. Norasetthada, A. Tantiworawit, E. Rattaritamrong, T. Rattanathammethee, S. Huntrakool, P. Piriyakhuntorn, C. Chai-Adisaksopha
Abstract Number: PB2107

Risk Factors of Venous Thromboembolism in Patients Undergoing Systemic Cancer Therapy: A Systematic Review and Meta-Analysis

S. Lee¹, A. Shenoy¹, M. Husien², D. Shi³, S. Parpia^4,5, P. Serrano¹
Abstract Number: PB2120

Risk Factors, Mortality and Costs of Cancer-Associated Thrombosis in Hospitalised Patients

W.Y. Jen¹, E. Santoso², S. Kumari², Y.L. Chee¹
Abstract Number: PB1810

Risk Factors, Outcomes, and Score Models of Serious Pulmonary Infection in Non-Splenectomized Immune Thrombocytopenia Adults

Y. Wu^1,2,3, P. Zhao^1,2,3, H. Fu^1,2,3, J. Zhang^1,2,3, Z. Zhang^1,2,3, Q. Huang^1,2,3, Q. Zeng^1,2,3, Y. He^1,2,3, X. Wang^1,2,3, H. Liu^1,2,3, Q. Jiang^1,2,3, H. Jiang^1,2,3, J. Lu^1,2,3, Y. Chang^1,2,3, L. Xu^1,2,3, X. Huang^1,2,3, X. Zhang^1,2,3
Abstract Number: PB2127

Risk of Arterial Thromboembolism in Cancer Patients: A Population-Based Cohort Study

F. Mulder^1,2, E. Horváth-Puhó², N. van Es¹, L. Pedersen², H.R. Büller¹, H.E. Bøtker³, H.T. Sørensen²
Abstract Number: PB2415

Risk of Bleeding of Concomitant Antiplatelet and Anticoagulation Therapy in Patient Treated for a Venous Thormboembolic Event

A. Fayol¹, M. Giraud², L. Plaisance³, L. Bertoletti⁴, I. Mahé³
Abstract Number: PB2474

Risk of Intracranial Bleeding in Patients with Primary Brain Cancer Receiving Therapeutic Anticoagulation for Venous Thromboembolism: A Meta-analysis

A. Porfidia¹, M. Giordano², C.L. Sturiale¹, S. D'Arrigo¹, M.P. Donadini³, A. Olivi², W. Ageno³, R. Pola²
Abstract Number: PB2320

Risk of Receiving a Permanent Work-Related Disability Pension After Incident Venous Thromboembolism

H. Jorgensen¹, E. Horváth-Puhó², K. Laugesen², S. Braekkan^1,3, J.-B. Hansen^1,4, H.T. Sørensen²
Abstract Number: PB2244

Risk of Recurrence after a First-lifetime Venous Thrombosis: Impact of Inherited Thrombophilia

M. Belhadj^1,2, H. Baccouche^1,2, F. Said^1,2, M.H. Houman^1,2, N. Ben Romdhane^1,2
Abstract Number: PB2105

Risk of venous Thromboembolism among Subgroups of Cancer Patients Undergoing Chemotherapy: Post-Hoc Analysis of the AVERT Trial

A.L. Nayak^1,2, A. Zahrai¹, R. Mallick^1,2, M. Carrier^1,2, P. Wells^1,2
Abstract Number: PB2178

Risk of Venous Thromboembolism in the Clinical Course of Osteosarcoma

M. Stals¹, F.H.J. Kaptein¹, R.E. Evenhuis², A.J. Gelderblom³, M.V. Huisman¹, R.W.D. Noten¹, H.H. Versteeg¹, M.A.J. Van de Sande², F.A. Klok¹
Abstract Number: PB2339

Risk of Venous Thrombosis in the Elderly: Lifestyle and its Joint Effect with Factor V Leiden and Prothrombin 20210A

H. Wang¹, M. Cushman², F. Rosendaal¹, A. van Hylckama Vlieg¹
Abstract Number: PB1344

Risk Stratification for Intracranial Hemorrhage in Adults with Immune Thrombocytopenia: A Retrospective Multicenter Study

P. Zhao^1,2,3, M. Hou⁴, H.-X. Liu⁵, R.-B. Huang⁶, H.-X. Yao⁷, T. Niu⁸, M. Jiang⁹, Y.-Q. Han¹⁰, Y. Liu¹¹, J.-D. Hu¹², Z.-P. Zhou¹³, H. Zhou¹⁴, L. Qiu¹⁵, L.-S. Zhang¹⁶, X. Wang¹⁷, H.-Q. Wang¹⁸, R. Feng¹⁹, L.-H. Yang²⁰, J. Sun²¹, X.-H. Zhang^1,2,3
Abstract Number: PB2101

Risks and Benefits of Antithrombotic Therapy in Polycythemia Vera: A Systematic Review

M. Laureano¹, L. Goodliffe¹, T. Barbui², D. Chu¹, A. Ferrari², D. Siegal¹
Abstract Number: PB2563

Rituximab before Pregnancy in Refractory Obstetrical Antiphospholipid Syndrome

A. Ciavarella, F. Gianniello, A. Artoni, M. Capecchi, P. Bucciarelli, F. Peyvandi, I. Martinelli
Abstract Number: PB1860

Rituximab Prolongs the Time to Relapse in Patients with Immune Thrombotic Thrombocytopenic Purpura: Analysis of Off-Label Use in Japan

M. Kubo¹, K. Sakai¹, Y. Yoshii², M. Hayakawa¹, M. Matsumoto¹
Abstract Number: PB0639

Rivaroxaban 20 mg Oce Daily Decreases Thrombin Generation in Patients with Venous Thromboembolism for up to 24 Hours

J. Kvasnicka¹, Z. Krska², I. Malikova³, T. Kvasnicka¹
Abstract Number: PB2391

Rivaroxaban for Extended Thromboprophylaxis in Acutely Ill Medical Patients 75 Years of Age or Older

W. Ageno¹, R.D. Lopes², M. Goldin³, R. Yusen⁴, G.W. Albers⁵, C.G. Elliott⁶, J.L. Halperin⁷, W.R. Hiatt⁸, G. Maynard⁹, P.G. Steg¹⁰, J.I. Weitz¹¹, E.Y. Suh¹², W. Lu¹², E.S. Barnathan¹², G.E. Raskob¹³, A.C. Spyropoulos³
Abstract Number: PB0612

Rivaroxaban Plasma Concentration Values and Risk Factors for Adverse Events in Patients Experiencing Bleeding: Results from a Prospective Study

J. Arjakse¹, R.E. Malmström^2,3, L. Gustafsson², H. Ilumets⁴, J. Kostjuk⁴, M. Märk⁴, M. Pikta^5,6, A. Pohanka^2,7,8, Y. Rönquist², T. Marandi^9,10
Abstract Number: PB2393

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the Mariner Trial

A.C. Spyropoulos¹, E.S. Barnathan², W. Ageno³, G.W. Albers⁴, C.G. Elliott⁵, W.R. Hiatt⁶, J.L. Halperin⁷, G. Maynard⁸, P.G. Steg⁹, J.I. Weitz¹⁰, T.E. Spiro¹¹, G.E. Raskob¹²
Abstract Number: PB0167

Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1

T. Petzold¹, M. Thienel¹, L. Dannenberg², P. Mourikis², C. Helten², R. M'Pembele², K. Trojovsky², Z. Zhang¹, R. Regenauer¹, J. Pircher¹, A. Ehrlich¹, E. Lüsebrink¹, L. Nicolai¹, T. Stocker¹, R. Brandl³, F. Röschenthaler⁴, J. Strecker¹, T. Hohlfeld⁵, M. Kelm², A. Polzin²
Abstract Number: PB2420

Rivaroxaban versus Warfarin for Treatment and Prevention of Recurrent Venous Thromboembolism in Obese Patients

O.S. Costa^1,2, J. Beyer-Westendorf³, V. Ashton⁴, D. Milentijevic⁴, K.T. Moore⁵, T.J. Bunz⁶, C.I. Coleman^1,2
Abstract Number: PB0477

RMean Platelet Volume to Lymphocyte Ratio and VTE Recurrence

A.C. Pizzarossa, S. Álvarez, F. Arévalo, C. Arocena, S. Gurruchaga, I. Gutiérrez, A. Pereira, V. Mérola, S. Grille, R. Martínez, C. Guillermo
Abstract Number: PB2185

Role of ADAMTS13, VWF and FVIII in Deep Vein Thrombosis

M.T. Pagliari¹, A. Cairo¹, M. Boscarino¹, I. Mancini², E. Pappalardo², I. Martinelli³, F.R. Rosendaal⁴, F. Peyvandi^1,2
Abstract Number: PB1895

Role of Anti Phosphatidylserine/Prothrombin Antibodies on Thrombin Generation and Protein C Resistance in Carriers of Antiphospholipid Antibodies

E. Pontara, M. Cattini, E. Bison, C.-Y. Cheng, G. Denas, M. Tonello, V. Pengo
Abstract Number: PB1323

Role of Bone Marrow-Derived Mesenchymal Stem Cell Defects in CD8+ CD28- Suppressor T-Lymphocyte Induction in Patients with Immune Thrombocytopenia and Associated Mechanisms

H. Li, R. Yang
Abstract Number: PB0383

Role of Endothelial Protein C Receptor Gene Polymorphisms (4678G>C and 6936A>G) in Young Indian DVT Patients

A. Sharma¹, K. Kishor¹, A. Biswas², R. Ranjan¹, R. Kumar¹, S. Tyagi¹, J. Oldenburg², R. Saxena¹, M. Mahapatra¹
Abstract Number: PB1821

Role of Formyl Peptide Receptor 2 (FPR2/ALX) and its Anti-Inflammatory Ligand, Lipoxin A4 Analogue (BML-111) in the Modulation of Platelet Function

S. AlOmar, D. Widera, S. Vaiyapuri
Abstract Number: PB1742

Role of HIF-2α in Promoting Thrombogenicity through PAI-1 Synthesis & EV-Releae during Adaptive Signalling in Human Platelets

R.L. Mallick¹, S.N. Chaurasia², D. Dash²
Abstract Number: PB0188

Role of Kunitz Domain 3 of Tissue Factor Pathway Inhibitor in Zebrafish

R. Raman, M. Ryon, A. Al Qaryoute, P. Jagadeeswaran
Abstract Number: PB1468

Role of Multidrug Resistance Protein 4 on Both Platelet Nitric Oxide Resistance and ADP Induced Platelet Aggregation

M.L. Guarino¹, I. Massimi¹, L. Alemanno¹, L. Conti², D.J. Angiolillo³, F.M. Pulcinelli¹
Abstract Number: PB1617

Role of Platelet Production/Destruction Imbalance on the Interindividual Variability in Aspirin Response in Diabetic and Non-diabetic Patients

R. Liani¹, P.G. Simeone¹, R. Tripaldi¹, A. Boccatonda², D. D'Ardes², M. Golato³, S. Ciotti¹, M. Luongo³, V. Creato¹, R. Pepe¹, F. Santilli¹
Abstract Number: PB1825

Role of Platelets in Processes of Myocardial Healing After Myocardial Ischemia and Reperfusion in Mice

M. Klier¹, A. Ayhan², L. Dannenberg², S. Gorressen³, A. Polzin², M. Elvers²
Abstract Number: PB1737

Role of Receptor for Advanced Glycation End-products (RAGE) in Human Platelets

D. Recabarren-Leiva^1,2, S. Wehinger^1,2, E. Fuentes^1,2, I. Palomo^1,2, M. Alarcón^1,2
Abstract Number: PB2411

Role of Residual Pulmonary Vascular Obstruction on the Risk of Long-Term Recurrence of Venous Thromboembolism After Pulmonary Embolism: A Cohort Study

M.P. Donadini¹, F. Boniardi², F. Dentali¹, W. Ageno¹
Abstract Number: PB1757

Role of RXRbeta in Platelet Function and Arterial Thrombosis

E. Lüsebrink¹, V. Warm¹, J. Pircher¹, Z. Zhang¹, P. Chambon², S. Massberg¹, C. Schulz¹, T. Petzold¹
Abstract Number: PB0353

Role of Serpine2 (PN-1) in Diabetic Nephropathy

L. Idir, K. Aymonnier, Y. Boulaftali, M.-C. Bouton, V. Arocas
Abstract Number: PB2575

Role of Thrombin Generation Potential (TGP) in Cesarean Sections and Vaginal Deliveries Puerperium to Guide Thromboprophylaxis. Preliminary Results

M. Perez De Palleja¹, P. Turcatti², A. Olivera², D. Raposo², C. Canessa², C. Guillermo³
Abstract Number: PB1960

Role of Thrombopoietin in Rescuing Vascular Niche of ITP Patients

Y. Jiao, X. Zeng, Z. Li, Y. Zhang, J. Ye
Abstract Number: PB1338

Romiplostim Treatment in Patients with Refractory Inmune Thrombocytopenia Purpura: Experience in a Single Center

B. Díaz Roldán¹, J.F. Domínguez Rodríguez¹, L. Martínez Molina², A.R. Carranco Falcón¹
Abstract Number: PB0509

Rotational Thromboelastometry – A Point of Care Tool to Assess Bleeding Risks in Hemophilia A and B

A. Kholmukhamedov¹, B. Benhar¹, B. Chea¹, R. Al Sawad¹, M. Schwaiger¹, R. Bottenus¹, A. Winkler²
Abstract Number: PB2537

Rotational Thromboelastometry (ROTEM) in Obstetric Population

B. Grand¹, M. Gonzalez Alcantara¹, D. Estevez², L. Voto¹
Abstract Number: PB0281

ROTEM Parameters As Bleeding Predictors In Pediatric Cardiac Surgery With Cardiopulmonary Bypass

D. Truong-Pham¹, T. Nguyen¹, S. Beaupha^1,2, T. Tran¹, T. Lai^1,2, T. Nguyen¹, P. Le-Thanh³, L.-X. Pham-Thi³, V. Le-Thanh⁴, P. Sa¹, D. Nguyen¹, T.-T. Nguyen¹
Abstract Number: PB0315

Routine Coagulation Assays for the Detection of Residual NOAC Levels in Patients Undergoing Elective Invasive Procedures

T. Vanassche¹, N. Li², M. Coppens³, A. Spyropoulos⁴, S. Schulman², S. Syed⁵, E. Arnaoutoglou⁶, J.D. Douketis²
Abstract Number: PB0792

Rutin and Rutin Succinate Improve Murine Survival in an Experimental Model of Acute Hemostatic Disturbances

A.T.A. Sachetto¹, A.O. de Souza², M.L. Santoro¹